Table 3.
Clinical trials of monoclonal antibodies against SARS-CoV-2 recorded in clinicaltrials.gov.
| Antibody name | Mechanism | Sponsor | Clinical trial identifier | Start-end | Participants number | Study location | Study protocol |
|---|---|---|---|---|---|---|---|
| Sarilumab (Kevzara®) (REGN88) (SAR153191) | Anti-IL-6 receptor | Regeneron & Sanofi | NCT04315298 | Mar 2020-Mar 2021 | 400 | Global (63 study locations) | Single IV low & high dose |
| Lisa Barrett Nova Scotia Health Authority Dalhousie University | NCT04321993 | Mar 2020-Feb 2021 | 1000 | – | 200 mg single SQ dose | ||
| Tocilizumab (TCZ) (Roactemra®) (Actemra®) | Anti-IL-6 receptor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Instituto de Salud Carlos III | NCT04332094 | Apr 2020-Sep 2020 | 276 | Spain | 162 mg q12 h SQ (one day) + hydroxychloroquine + Azithromycin |
| National Cancer Institute, Naples | NCT04317092 | Mar 2020-Dec 2020 | 330 | Global (27 study locations) | 8 mg/kg (max 800 mg per dose) q 12 h | ||
| University of Chicago | NCT04331795 | Apr 2020-Jul 2020 | 50 | USA | Single low dose (starting with 80 mg) or high dose (starting with 200 mg), repeat dose if needed | ||
| University Hospital Inselspital, Berne Roche Pharma AG | NCT04335071 | Apr 2020-Oct 2020 | 100 | Switzerland | 8 mg/kg (max 800 mg per dose), IV infusion; repeat dose if needed | ||
| Hoffmann-La Roche | NCT04320615 | Apr2020-Aug 2021 | 330 | – | |||
| University of L'Aquila | NCT04332913 | Apr 2020- Dec 2020 | 30 | – | – | ||
| Tongji Hospital | NCT04306705 | Feb 2020-May 2020 | 120 | China | 8 mg/kg IV infusion | ||
| Peking University First Hospital | NCT04310228 | Mar 2020-May 2020 | 150 | China | 8 mg/kg (max 800 mg per dose) + favipiravir | ||
| MedSIR | NCT04335305 | Mar 2020-May 2020 | 24 | – | Single dose of 8 mg/kg (max 800 mg per dose), IV infusion + pembrolizumab | ||
| Centre Leon Berard | NCT04333914 | Apr 2020-Jun 2020 | 273 | France | Single dose 400 mg IV + nivolumab + chloroquine | ||
| University Hospital, Ghent | NCT04330638 | Apr 2020-Sep 2020 | 342 | Belgium | Single dose of 8 mg/kg (max 800 mg per dose), IV infusion | ||
| Marius Henriksen Lars Erik Kristensen | NCT04322773 | Mar 2020-Jun 2021 | 200 | Denmark | Single dose 400 mg IV | ||
| Università Politecnica delle Marche | NCT04315480 | Mar 2020-Apr 2020 | 30 | Italy | Single IV dose of 8 mg/kg | ||
| Assistance Publique - Hôpitaux de Paris | NCT04331808 | Mar 2020-Mar 2021 | 240 | – | IV dose of 8 mg/kg, repeat dose if needed | ||
| Siltuximab (Sylvant®) | Anti-IL-6 | University Hospital, Ghent Belgium Health Care Knowledge Centre | NCT04330638 | Apr 2020-Sep 2020 | 342 | Belgium | Single dose of 11 mg/kg IV infusion + anakinra + tocilizumab |
| Judit Pich Martínez | NCT04329650 | Apr 2020-May 2020 | 100 | Spain | Single dose of 11 mg/kg IV infusion | ||
| A.O. Ospedale Papa Giovanni XXIII | NCT04322188 | Mar 2020-May 2020 | 50 | Italy | – | ||
| Bevacizumab (An ke da) | VEGF inhibitor | Qilu Hospital of Shandong University | NCT04305106 | Mar 2020-Jun 2020 | 140 | China | 7.5 mg/kg IV |
| Qilu Hospital of Shandong University Renmin Hospital of Wuhan University Moriggia-Pelascini Gravedona Hospital | NCT04275414 | Feb 2020-Apr 2020 | 20 | China | 500 mg IV | ||
| Emapalumab (Gamifant®) | Anti-IFNγ | Swedish Orphan Biovitrum | NCT04324021 | Mar 2020-Jul 2020 | 54 | Italy | IV infusion every three days for a total of five infusions. Day 1: 6 mg/kg. Days 4, 7, 10 and 13: 3 mg/kg + anakinra |
| Thymosin | Anti-PD-1 | Southeast University, China | NCT04268537 | Feb 2020-Apr 2020 | 120 | China | 1.6 mg SQ, qd (for five days) |
| Pembrolizumab (MK-3475) (Keytruda®) | MedSIR | NCT04335305 | Mar 2020-May 2020 | 24 | – | Single dose of 200 mg IV infusion + tocilizumab | |
| Nivolumab | Centre Leon Berard | NCT04333914 | Apr 2020-Jun 2020 | 273 | France | Single dose of 0.3 mg/kg IV infusion + tocilizumab + chloroquine | |
| Eculizumab (Soliris®) | Distal complement inhibitor, preventing formation of the membrane attack complex | Hudson Medical | NCT04288713 | – | – | – | – |
| Meplazumab | Anti -CD147 | Tang-Du Hospital | NCT04275245 | Feb 2020-Dec 2020 | 20 | China | 10 mg IV infusion, every two days |